GastroenterologyHER2+ Gastric Canceroncology
Spatial Profiling of Resistance Mechanisms in HER2-Positive Gastric Cancer: Insights from Patient-Matched Analysis
By MedXY|Mar 27, 2026
This report examines spatial transcriptomic data from HER2+ gastric cancer patients to identify resistance mechanisms to trastuzumab and T-DXd, including EMT and ERAD pathway activation.